Xeris Biopharma's 2023 Cash Utilization Expected To Be $52M-$57M
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma expects its cash utilization for the year 2023 to be between $52M and $57M.
October 16, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Xeris Biopharma's projected cash utilization for 2023 is between $52M and $57M.
The news directly pertains to Xeris Biopharma's financial planning and cash management for the year 2023. However, without additional context such as comparison to previous years or industry averages, it's difficult to predict the impact on the stock price. Hence, the score is neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100